BioSpace News Archive

Biotech Beach

Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders

Arcturus is currently not aware of any other matters that will come before the meeting.

January 31, 2018
·
6 min read
Pharm Country

Reaction Biology Launches Ion Channel Division

RBC has retained their senior scientist personnel with decades of electrophysiology experience and has begun providing services.

January 31, 2018
·
1 min read
Genkyotex Reports December 31, 2017 Cash Position and Provides Business Update

The cash position includes the €2.4 million payment of the 2016 Research Tax Credit received on December 2017.

January 31, 2018
·
5 min read
Nemaura Announces Positive Results for its SugarBEAT European Clinical Program

The summary results were taken from a 25 patient cohort of the previously reported European three-stage 75 patient Clinical study, consisting of 80% Type 1 and 20% Type 2 Diabetics.

January 31, 2018
·
4 min read
Drug Development

MPI’s Spinout Oncology Venture Announces Positive Interim Results From a Phase I/II DRP Guided Study of Liplacis in Heavily Pretreated Breast Cancer Patients

The selection of patients for the Phase 1/2 study is aided by the MPI developed DRP® companion diagnostic tool, allowing inclusion of those patients most likely to respond to treatment.

January 31, 2018
·
7 min read
Policy

Sanofi, DNDi Seek European Medicines Agency Review for Sleeping Sickness Treatment

Fexinidazole would be first all-oral treatment* under investigation for both first and second stages of sleeping sickness.

January 31, 2018
·
6 min read
Change in the Number of Shares and Votes in Immunicum

The number of shares and votes in Immunicum has, as a result of a rights issue of shares, increased with 24,999,990, from 25,958,541 to 50,958,531.

January 31, 2018
·
1 min read
Policy

Sientra Provides Update on FDA Review of U.S. Manufacturing Facility

The Company believes that the information requested by the FDA related to this third and final outstanding submission can be addressed quickly and is working closely with the FDA to resolve these matters in a timely manner.

January 31, 2018
·
5 min read
Drug Development

A new Publication Confirms AZtherapies’s Innovative Drug Combination Approach to Address the Neuroinflammation Response Via Neuro-Immunology and Amyloid Beta Accumulation Associated With Neurodegeneration and Alzheimer’s Disease.

The lead product candidate, a combination multi-faceted treatment using two re-engineered drugs, cromolyn and ibuprofen, ALZT-OP1, is being studied in a Phase 3 Early Alzheimer’s clinical trial, the COGNITE trial.

January 31, 2018
·
3 min read
Eurofarma Group Release: Unprecedented Project in Brazilian Industry Has an Investment of R$ 8.4 Million

Embrapii will finance R$ 1.8 million per company with non-refundable resources, that is, without the need to refund the amount.

January 31, 2018
·
6 min read